|
2025 was a record year for Boehringer in terms of licensing deals, with a majority of these agreements being oncology or immunology-focused.
|
 |
|
Before eyeing a Nasdaq ticker, AI drug discovery specialist Generate already attracted interest from Amgen and Novartis.
|
|
|
Yuviwel’s approval marks a more convenient option compared to BioMarin’s daily injection Voxzogo.
|
|
|
The approval follows PEGASUS Phase III trial assessing Palynziq efficacy and safety compared to diet alone in adolescents with PKU.
|
|
|
The CHMP’s recommendation is based on LIBERTY-CUPID data, including two Phase III and the CUPIDKids studies.
|
|
